Evidence map›Paper›PMID 35113452›Full record

ArticleAllergy2022

Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper.

Karin B Fieten, Marieke T Drijver-Messelink, Annalisa Cogo, Denis Charpin, Milena Sokolowska, Ioana Agache, Luís Manuel Taborda-Barata, Ibon Eguiluz-Gracia, Gerrit J Braunstahl, Sven F Seys and 22 more

Open access · bronzeAbstract readConsensus Statement
In one paragraph

Article in Allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
7.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Indoor Environmental Exposures and Their Relationship to Allergic Diseases.The journal of allergy and clinical immunology. In practice · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 14 countries.

Karin B FietenSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Wolfgang, Switzerland.
Marieke T Drijver-MesselinkDutch Asthma Center Davos, Davos, Switzerland.
Annalisa CogoCenter for Exercise and Sport Science, University of Ferrara, Ferrara, Italy.
Denis CharpinDepartment of Pulmonology and Allergy, Faculty of Medicine, North Hospital, Aix-Marseille University, Marseille, France.
Milena SokolowskaSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Wolfgang, Switzerland.ORCID 0000-0001-9710-6685
Ioana AgacheFaculty of Medicine, Transylvania University, Brasov, Romania.ORCID 0000-0001-7994-364X
Luís Manuel Taborda-BarataNuESP-Planetary Health Study Unit, Faculty of Health Sciences & CICS-Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.
Ibon Eguiluz-GraciaAllergy Unit and Research Group, Hospital Regional Universitario de Malaga, Malaga, Spain.ORCID 0000-0002-3774-931X
Gerrit J BraunstahlDepartment of Pulmonology, STZ Centre of Excellence for Asthma and COPD, Franciscus Group, Rotterdam, The Netherlands.ORCID 0000-0001-7671-3742
Sven F SeysAllergy and Clinical Immunology Research Group, Department of Microbiology, Immunology & Transplantation, KU Leuven, Leuven, Belgium.
Maarten van den BergeDepartment of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Konrad E BlochDepartment of Respiratory Medicine, University and University Hospital of Zurich, Zurich, Switzerland.
Silvia UlrichDepartment of Respiratory Medicine, University and University Hospital of Zurich, Zurich, Switzerland.
Carlos Cardoso-ViguerosDepartment of Allergology, University Hospital of Zurich, Zurich, Switzerland.
Jasper H KappenDepartment of Pulmonology, STZ Centre of Excellence for Asthma and COPD, Franciscus Group, Rotterdam, The Netherlands.
Anneke Ten BrinkeDepartment of Pulmonary Diseases, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
Markus KochAlpenklinik Santa-Maria, Oberjoch- Bad Hindelang, Germany.
Claudia Traidl-HoffmannChristine Kühne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.ORCID 0000-0001-5085-5179
Pedro da MataInstituto Clinico de Allergologia, Lisbon, Portugal.
David J PrinsDutch Asthma Center Davos, Davos, Switzerland.
Suzanne G M A PasmansDepartment of Dermatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0003-1018-4475
Sarah BendienDepartment of Pulmonology, HAGA Teaching Hospital, The Hague, The Netherlands.ORCID 0000-0003-2069-9181
Maia RukhadzeCenter of Allergy & Immunology, Tbilisi, Georgia.ORCID 0000-0002-1413-8161
Mohamed H ShamjiImmunomodulation and Tolerance Group, Allergy and Clinical Immunology, Department of National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-3425-3463
Mariana CoutoAllergy Unit, Hospital CUF Descobertas, Lisbon, Portugal.ORCID 0000-0003-4987-9346
Hanneke Oude ElberinkGroningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Diego G PeroniDepartment of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy.
Giorgio PiacentiniPediatric Section, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Verona, Italy.
Els J M WeersinkDepartment of Pulmonology, Location AMC, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Matteo BoniniDepartment of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Rome, Italy.
Lucia H M Rijssenbeek-NouwensDutch Asthma Center Davos, Davos, Switzerland.
Cezmi A AkdisSwiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos Wolfgang, Switzerland.
Nederlands Astmacentrum Davos · CHUniversity Hospital of Zurich · CHUniversity of Zurich · CHSint Franciscus Gasthuis · NLUniversity Medical Center Groningen · NLAix-Marseille Université · FRAllergan (Ireland) · IEAmsterdam University Medical Centers · NLCUF Porto Hospital · PTErasmus MC · NLHaga Hospital · NLHospital Regional Universitario de Málaga · ESHospital Universitário de Santa Maria · BRKU Leuven · BELung Institute · USMedisch Centrum Leeuwarden · NLTransylvania University of Brașov · ROUniversità Cattolica del Sacro Cuore · ITUniversity Geomedi · GEUniversity of Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently available European Alpine Altitude Climate Treatment (AACT) programs combine the physical characteristics of altitude with the avoidance of environmental triggers in the alpine climate and a personalized multidisciplinary pulmonary rehabilitation approach. The reduced barometric pressure, oxygen pressure, and air density, the relatively low temperature and humidity, and the increased UV radiation at moderate altitude induce several physiological and immunological adaptation responses. The environmental characteristics of the alpine climate include reduced aeroallergens such as house dust mites (HDM), pollen, fungi, and less air pollution. These combined factors seem to have immunomodulatory effects controlling pathogenic inflammatory responses and favoring less neuro-immune stress in patients with different asthma phenotypes. The extensive multidisciplinary treatment program may further contribute to the observed clinical improvement by AACT in asthma control and quality of life, fewer exacerbations and hospitalizations, reduced need for oral corticosteroids (OCS), improved lung function, decreased airway hyperresponsiveness (AHR), improved exercise tolerance, and improved sinonasal outcomes. Based on observational studies and expert opinion, AACT represents a valuable therapy for those patients irrespective of their asthma phenotype, who cannot achieve optimal control of their complex condition despite all the advances in medical science and treatment according to guidelines, and therefore run the risk of falling into a downward spiral of loss of physical and mental health. In the light of the observed rapid decrease in inflammation and immunomodulatory effects, AACT can be considered as a natural treatment that targets biological pathways.

Indexed as

AltitudeAsthmaAllergensAnimalsClimateHumansPyroglyphidaeQuality of LifeAllergensaltitudeasthmaclimateenvironmentpulmonary rehabilitation

Identifiers

PMID35113452
PMCPMC9305916
OpenAlexW4210708980

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.